Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Ocera Therapeutics

Request full access

Biopharmaceutical company developing novel therapeutics for patients with acute and chronic liver diseases

Palo Alto, United StatesFounded 2005Biotech & Life Sciences

About Ocera Therapeutics

Ocera Therapeutics, Inc. was a clinical-stage biopharmaceutical company that concentrated on creating treatments for liver diseases. The company was founded in 2005 and operated from Redwood City, California. A significant event in the company's history was the merger with Tranzyme, Inc. in July 2013, after which the combined entity continued under the Ocera Therapeutics name, led by President and CEO Linda S. Grais, MD. This merger was followed by a $20 million private placement from several venture capital firms. The company's journey culminated in its acquisition by Mallinckrodt plc, a deal announced in November 2017 and finalized in December 2017. Mallinckrodt acquired Ocera for an initial $42 million, with potential for an additional $75 million based on development and sales milestones. Following the acquisition, Ocera became an indirect, wholly-owned subsidiary of Mallinckrodt and ceased to be a publicly traded company on the Nasdaq exchange.

Ocera's business model was centered on the development and eventual commercialization of its lead drug candidate, OCR-002 (ornithine phenylacetate), targeting orphan and other serious liver diseases with high unmet medical need. The company's market focus was on patients with hepatic encephalopathy (HE), a neuropsychiatric complication of acute or chronic liver disease caused by high ammonia levels (hyperammonemia). The potential U.S. market for HE was estimated to be substantial, with around 200,000 hospitalizations annually.

The company's core product, OCR-002, is an ammonia scavenger designed to lower dangerously high ammonia levels in the blood. It functions through a dual-mode action that does not rely on the liver, which is compromised in these patients. Once administered, OCR-002 breaks down into ornithine and phenylacetate. Ornithine helps convert ammonia into glutamine in the muscles, and phenylacetate combines with this glutamine to form phenylacetylglutamine, which is then excreted by the kidneys. This mechanism provides an alternative pathway for ammonia removal. OCR-002 was developed in both an intravenous (IV) formulation for acute HE in hospitalized patients and an oral version for maintenance therapy to prevent recurrence. The U.S. FDA had granted OCR-002 both Orphan Drug designation and Fast Track status. Despite a Phase 2b trial not meeting its primary endpoint, the drug demonstrated a significant effect on lowering ammonia levels, prompting Mallinckrodt to acquire it with the belief that trial design, not the drug itself, was the issue.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2011
Open positions
None listed
Dealroom signal
20.3/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Links
Website

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Nov 2017 $42M $42M Mallinckrodt —
POST IPO DEBTDebt Aug 2015 $20M — Greenspring Associates · Silicon Valley Bank · Oxford Finance —
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Ocera Therapeutics website traffic

Latest recorded traffic for Ocera Therapeutics is 240 monthly website visits.

Latest monthly visits240
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Ocera Therapeutics in the Palo Alto ecosystem

Live from Dealroom

The Ocera Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

20 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Sofinnova Investments
  • Domain Associates
  • Thomas McNerney & Partners

Series B and later15 investors entered at this stage

Other known investors2 additional known investors

  • Mallinckrodt
  • Redmont Capital
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Palo Alto HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Ocera Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ocera Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.